Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.

While blockade of the cytotoxic T-lymphocyte antigen-4 (CTLA-4) T cell regulatory receptor has become a commonly utilized strategy in the management of advanced melanoma, many questions remain regarding the use of this agent in patient populations with autoimmune disease. We present a case involving the treatment of a patient with stage IV melanoma and ulcerative colitis (UC) with anti-CTLA-4 antibody immunotherapy. Upon initial treatment, the patient developed grade III colitis requiring tumor necrosis factor-alpha (TNF-α) blocking antibody therapy, however re-treatment with anti-CTLA-4 antibody following a total colectomy resulted in a rapid complete response accompanied by the development of a tracheobronchitis, a previously described extra-intestinal manifestation of UC. This case contributes to the evolving literature on the use of checkpoint inhibitors in patients also suffering from autoimmune disease, supports future clinical trials investigating the use of these agents in patients with autoimmune diseases, and suggests that an understanding of the specific molecular pathways involved in a patient's autoimmune pathology may provide insight into the development of more effective novel combinatorial immunotherapeutic strategies.

A microwave metamaterial with integrated power harvesting functionality

We present the design and experimental implementation of a power harvesting metamaterial. A maximum of 36.8% of the incident power from a 900 MHz signal is experimentally rectified by an array of metamaterial unit cells. We demonstrate that the maximum harvested power occurs for a resistive load close to 70 Ω in both simulation and experiment. The power harvesting metamaterial is an example of a functional metamaterial that may be suitable for a wide variety of applications that require power delivery to any active components integrated into the metamaterial. © 2013 AIP Publishing LLC.